Data Shows Cerevel's Emraclidine Does Not Induce High Blood Pressure In Schizophrenia Patients

  • Cerevel Therapeutics Holdings, Inc. CERE announced results from the Phase 1 trial studying the effect of emraclidine on 24-hour ambulatory blood pressure over eight weeks in schizophrenia patients. 
  • The trial's objective was to accurately characterize any potential blood pressure effect for both doses of emraclidine studied (10 and 30 mg QD).
  • On the primary endpoint, emraclidine demonstrated a mean change from baseline at week eight in 24-hour ambulatory systolic blood pressure (SBP) of -2.7 mmHg for the 10 mg QD group and -0.4 mmHg for the 30 mg QD group. 
  • Related: Mizuho Is Bullish On This Schizophrenia-Focused Stock, Read Why.
  • The upper bound was -0.3 mmHg for the 10 mg QD group and 2.1 mmHg for the 30 mg QD group. 
  • As a result, the trial ruled out an increase in blood pressure for both doses.
  • The trial's secondary endpoints demonstrated findings consistent with the primary endpoint, corroborating the overall trial results. 
  • Emraclidine was generally well-tolerated in this trial, with a side effect profile consistent with prior trials.
  • This ambulatory blood pressure monitoring trial was designed in line with FDA guidance.
  • Price Action: CERE shares are up 30.34% at $33.04 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!